NFE2L2 and cancer: However, metabolic ROS is potentially detrimental and a critical issue for cancer cells is to keep ROS at levels beneficial for tumor development but insufficient to induce cell death (Nagel et al, 2016; Storz, 2017), which is counterbalanced by anti‐oxidant processes such as the transcription factor NRF2 (also known as NFE2L2)‐dependent oxidative stress‐responsive programs (DeNicola et al, 2011).